<DOC>
	<DOCNO>NCT00478686</DOCNO>
	<brief_summary>The goal laboratory research study identify possible difference gene among patient breast cancer treat surgery . Researchers want find difference gene may increase risk side effect capecitabine .</brief_summary>
	<brief_title>Association Dihydropyrimidine Dehydrogenase ( DPYD ) Variants With Toxicity Related Capecitabine</brief_title>
	<detailed_description>If agree take part study , 1 blood sample ( 2 tablespoon ) drawn use genetic research . If unable provide blood sample , researcher collect leftover tissue sample previously collect tumor tissue ( time breast cancer diagnosis ) . The tumor sample use genetic research . After blood draw tissue collection , participation study . The blood sample genetic research store Myriad Laboratories . Before blood and/or tissue send Myriad Laboratories banking , name personal identifying information cod protect privacy . M. D. Anderson oversight leftover tissue and/or blood bank Myriad Laboratories additional research . This investigational study . Up 210 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Patients must register protocol ID 01580 patient randomized receive capecitabine include study . 2 . Patients must sign informed consent protocol . 1 ) There exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Dihydropyrimidine Dehydrogenase</keyword>
	<keyword>DPYD</keyword>
	<keyword>DPYD Variants</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>